Aargh - another mystery!, page-2

  1. 11,786 Posts.
    lightbulb Created with Sketch. 1720
    Maybe because it isn't vla?

    Three trials with Keytrunda Melanoma and Sydney:

    https://www.clinicaltrials.gov/ct2/results?term=keytruda sydney melanoma

    Keytrunda is in (or has planned) 606 different trials overall:

    https://www.clinicaltrials.gov/ct2/...recrs=a&age_v=&gndr=&type=&rslt=&Search=Apply

    On another note I was thinking about a counter offer.

    Sirtex attracted one, but then that's making money.

    Perhaps the only possible counter bidder for vla is BristolMS, as they are the only other company than Merck to have some data with their own drug. But would BMS really want to do a big pharma bidding war with Merck for vla? vla is not a must have for BMS, if it was they would have snapped us up long ago.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.